UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 23, 2009 (January 21, 2009)
King Pharmaceuticals, Inc.
(Exact name of registrant as specified in charter)
| |
|
|
|
|
| Tennessee
|
|
001-15875
|
|
54-1684963 |
| |
| (State or other jurisdiction
|
|
(Commission
|
|
(I.R.S. Employer |
| of incorporation)
|
|
File Number)
|
|
Identification No.) |
| |
|
|
| 501 Fifth Street, Bristol, Tennessee
|
|
37620 |
| |
| (Address of principal executive offices)
|
|
(Zip Code) |
Registrant’s telephone number, including area code: (423) 989-8000
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Item 8.01. Other Events.
On January 21, 2009, King Pharmaceuticals, Inc. issued a press release announcing that the
U.S. District Court for the Eastern District of New York in the case of King Pharmaceuticals, Inc.,
et al. v. Eon Labs, Inc., Case No. 04-cv-5540 (DGT), issued an Order invalidating United States
Patent Nos. 6,407,128 and 6,683,102, two patents relating to SKELAXIN® (metaxalone). A copy of the
press release is attached as Exhibit 99.1 to this report.
Item 9.01
(d) Exhibits
| |
|
|
| Exhibit No. |
|
Description |
|
|
|
99.1
|
|
Press Release issued by King
Pharmaceuticals, Inc. dated January 21, 2009. |